• The FDA Approved a Promising New Shot to Treat Migraines and Now the Drugmakers' Stocks Are Rising

    5 monthes ago - By Fortune

    The stock prices of Amgen amgn and Novartis nvs have popped after the pharmaceutical companies won U.S. approval for a new shot that treats migraines .
    Aimovig is a monthly shot that's the first in a new class of anti-migraine treatments, coming at a cost of $6,900 per year without insurance. The companies announced Thursday that the U.S. Food and Drug Administration had given it the all-clear.
    The new treatment, which can be administered with an autoinjector, should now be available within a week. The companies say Aimovig significantly reduces monthly migraine days.
    Amgen's stock rose...
    Read more ...

     

  • The FDA just approved the first drug designed to prevent migraines

    5 monthes ago - By Fast Company

    The drug is called Aimovig and is made by pharmaceutical giants Amgen and Novartis.
    The drug is called Aimovig and is made by pharmaceutical giants Amgen and Novartis. It is delivered via injection with a device that is similar to an insulin pen, reports the New York Times. Aimovig works by blocking a protein fragment called CGRP, which instigates and perpetuates migraines. Aimovig will be available within the next week-potentially being a life-changing medication for millions of Americans afflicted by migraines.
    Read more ...